This week on the Wealthing Podcast, host Alicia Castillo Holley sits down with keynote speaker and workshop facilitator Stefan Wetterholm to unpack his transformative framework, "From Noise to Clarity." Stefan shares how a simple story about a Japanese consultant—who optimized a factory floor by placing a single mark on the ground—inspired him to champion extreme simplicity in overwhelming, complex environments.

The conversation dives deep into the human element of leadership and career fulfillment. Stefan shares a striking example of helping an individual double their salary simply by reframing their value through the right question. He challenges listeners to find their "inner locus of control" and offers a litmus test for true career resonance: Would you still do this work if success or money weren't guaranteed? Stefan also discusses his updated book, FUN: The Human Advantage. Leadership in the Age of AI, and shares a glimpse into his personal life, living full-time in Bali after initially planning to split his time with Italy.

About Stefan: Stefan Wetterholm is an international speaker and author of The Human Advantage: Leadership in the Age of AI. (Free digital download on Wetterholm.com) His work focuses on a simple question: How do we think clearly and focus on what matters in a world filled with noise?

Having worked with more than 1,000 founders, leaders, and teams through longer transformational programs, Stefan helps people uncover clarity, make better decisions, and create meaningful momentum. At a time when AI can generate endless information, Stefan helps founders and leaders move from noise to clarity—so they can focus on what matters most.

Connect with Stefan: www.linkedin.com/in/stefanwetterholm

Stefan's Website: www.wetterholm.com

🌐 Wealthing Club: www.wealthing.club

This week on the Wealthing Podcast, Alicia is joined by Raphael Roettgen, the founding partner of space venture fund E2MC, to detail his fascinating career evolution from investment banking and hedge fund management into the frontier sector of space investment. As a space investment specialist and the founder of E2MC, a venture capital fund dedicated to early-stage space startups, Raphael reflects on the trajectory of the commercial space ecosystem. He shares insights from his early investment in SpaceX over a decade ago, and underscores how the sector has evolved into a cornerstone of future global infrastructure.

The conversation explores Raphael's distinct investment philosophy, which prioritizes a founder's potential for monumental success over standard, conservative risk-mitigation frameworks. Alongside his venture work, Raphael discusses his role in shaping the next generation of aerospace innovators through his entrepreneurship courses at institutions like the Swiss Federal Institute of Technology in Lausanne. Moving beyond financial returns, the discussion touches upon Raphael's holistic view of wealth as a vehicle for a meaningful life. The conversation highlights how space exploration can yield profound, tangible benefits for humanity on Earth, ranging from microgravity manufacturing to groundbreaking discoveries in biotech and medicine.

About Raphael: Raphael Roettgen is the founding partner of E2MC (Earth-to-Mars Capital), a space-focused early-stage venture capital firm with over 30 space investments globally to date. E2MC also co-founded two space accelerators: KickSky, India's first space accelerator, and the Orbital Edge accelerator in the U.S. (in partnership with ISS National Lab).

Raphael is also Executive Chairman of Space Asset Acquisition Corp., a $230 million NASDAQ-listed space-focused SPAC, and a co-founder and acting CEO of Prometheus Life Technologies, a Swiss space biotech startup focused on organoids. He has lectured on space entrepreneurship and investing at universities including the Swiss Federal Institute of Technology Lausanne (EPFL), International Space University (ISU), Nova Business School, HBS and Stanford. Raphael hosts the popular Space Business Podcast, and is the author of "To Infinity," an introductory book on the space economy.

Previously, he held senior roles at global investment banks and hedge funds. He holds degrees in finance and psychology from the University of Pennsylvania, machine learning from PUC-Rio, and space studies from the International Space University, where he also serves as adjunct faculty and a governing member.

Connect with Raphael: www.linkedin.com/in/raphaelroettgen

E2MC Space: www.e2mc.space

🌐 Wealthing Club: www.wealthing.club

This week on The Wealthing Podcast, Alicia is joined by Jason Bock, CEO of CTMC, for an inspiring look inside the front lines of cancer treatment innovation at MD Anderson Cancer Center. Jason details the revolutionary shift toward personalized, single-dose cell therapies that engineer a patient's own T-cells to target and eliminate cancer. This cutting-edge approach represents a fundamental pivot in medicine—moving away from chronic, ongoing disease management and toward treatments designed with true curative intent, allowing individuals to completely reclaim their lives from a cancer diagnosis.

The conversation follows Jason's personal career evolution within biotech and biopharma, highlighting his move to Houston's premier oncological ecosystem to maximize patient impact. Through the lens of his team's breakthroughs, Jason reflects on the nature of scientific progress, where the ultimate goal is often proving oneself wrong in order to discover what is truly right. By embracing seemingly impossible challenges and treating immuno-oncology not as an outlier, but as a central pillar of healthcare, Jason illustrates how leaning into difficult work creates a deeply purposeful life that directly restores health to patients and their families.

About Jason: Jason Bock, PhD, is CEO of CTMC, a joint venture between Resilience + MD Anderson Cancer Center. Formed in May 2022 to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Anderson's clinical trial capabilities. In 2019, Jason was recruited by MD Anderson from Teva Pharmaceuticals to build the Biologics Development group. The group purchased a 60,000 SF facility in the Texas Medical Center and has since formed multiple partnerships with both MD Anderson faculty and early-stage biotech firms to bring their products through the IND process. Previously, Jason was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. He joined Teva through the acquisition of CoGenesys, a private biotech firm as a spinoff from Human Genome Sciences (HGS), where he worked after completing a PhD at Stanford University in Molecular & Cellular Physiology.

About CTMC: CTMC is a co-development accelerator formed through a joint venture between Resilience and MD Anderson Cancer Center to fast-track the development and manufacturing of next-generation cell therapies for cancer. Located in the heart of the Texas Medical Center, CTMC combines deep expertise in TIL and CAR-T platforms with integrated manufacturing and regulatory capabilities to accelerate the path from discovery to IND. As a true partner, we work side-by-side with cell therapy innovators to advance programs into the clinic faster and chart a clear course to commercial readiness.

Connect with Jason: www.linkedin.com/in/jason-b-bock/

CTMC Website: www.ctmc.com ,

CTMC LinkedIn: www.linkedin.com/company/ctmcplus/

🌐 Wealthing Club: www.wealthing.club